Predictive Factors of Stent Patency in Iliofemoral Venous Diseases in a Multicentre Cohort Study

• DOI: 10.1016/j.ejvs.2023.01.005
• Publication Date: 2023-01-13T08:36:09Z
• Authors: Olivier Espitia; Frédéric Douane; Jeanne Hersant; Fabrice Abbadie; Jonathan Sobocinski; Jean-François Hea...; Annaïg Miossec; François-Xavier L...; Olivier Hartung; Francine Thouveny; Arthur David; Samir Henni; Alexis F. Guédon; Agathe de Préville; Hervé Rousseau; Paul Revel-Mouroz; Béatrice Guyomarch; Guillaume Mahé; Giovanni Gautier; Blandine Maurel
• Keywords: Venous Thrombosis; Cohort Studies; Treatment Outcome; [SDV]Life Sciences [q-bio]; Humans; Anticoagulants; Stents; Iliac Vein; Platelet Aggregation Inhibitors; Vascular Patency; Postthrombotic Syndrome; Retrospective Studies; 3. Good health

This study assessed primary stent patency predictive factors in three groups of patients with history of lower limb (LL) vein thrombosis: non-thrombotic iliac vein lesion (NIVL), acute deep vein thrombosis (aDVT), and post-thrombotic syndrome (PTS).Consecutive patients from January 2014 to December 2020 with history of LL vein stenting from seven hospitals were included. All patients received an iliac or common femoral venous stent and had at least a six month follow up available with stent imaging. Anticoagulant and antiplatelet therapy strategies employed after venous stenting are reported and compared between groups.This study included 377 patients: 134 NIVL, 55 aDVT, and 188 PTS. Primary patency was statistically significantly higher in the NIVL group (99.3%) compared with the PTS group (68.6%) (p < .001) and the aDVT group (83.6%) (p = .002). PTS patients received a statistically significantly greater number of stents (p < .001) and had more stents below the inguinal ligament (p < .001). Median follow up was 28.8 months (IQR 16, 47). Discontinuation of antiplatelet therapy at the last assessment was 83.6% for NIVL, 100% for aDVT, and 95.7% for the PTS group (p < .001). Discontinuation of anticoagulation therapy at the last assessment was 93.2% for NIVL, 25.0% for aDVT, and 70.3% for the PTS group (p < .001). The only predictor of worse primary patency in the aDVT group was long term anticoagulation before stenting.Patients with NIVL have better primary patency after venous stenting than patients with venous thrombotic disorders. Long term anticoagulation before stenting was the only factor associated with poorer primary patency in patients with aDVT.